News Releases

Jun 21, 2019
Applied Therapeutics Reports First Quarter 2019 Financial Results
-Strengthened Financial Position with Recent Initial Public Offering- - Phase 1/2 Trial AT-007 in Adults with Galactosemia Expected to Start This Month - - Pivotal Phase 2/3 Trial for AT-001 in Diabetic Cardiomyopathy Expected to Start Later This Year - NEW YORK , June 21, 2019 (GLOBE NEWSWIRE) --
Jun 07, 2019
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions
AT-001, a novel, potent and selective aldose reductase inhibitor, is expected to start a pivotal study later this year NEW YORK , June 07, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates